Clinical Trial: NCT03888105
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Regeneron Pharmaceuticals |
| Information Provided By: | Regeneron Pharmaceuticals |
| Last Update Posted: | 2026-07-31 |
Study Overview
Brief Summary
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).
The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab.
The study is looking at several other research questions, including:
- To see if odronextamab works to destroy cancer cells
- Side effects that may be experienced by people taking odronextamab
- How odronextamab works in the body
- How much odronextamab is present in the blood
Official Title
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL)
Intervention / Treatment
- Drug: Odronextamab
Other Study ID Numbers
- R1979-ONC-1625
- 2017-002139-41
- 2024-511747-25-00
- 2017
Start Date (Actual)
2019-11-13
Primary Completion Date (Actual)
2026-06-17
Study Completion Date (Estimated)
2028-12-15
Enrollment (Actual)
515
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Regeneron Pharmaceuticals |
| Information Provided By: | Regeneron Pharmaceuticals |
| Last Update Posted: | 2026-07-31 |
Study Overview
Brief Summary
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).
The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab.
The study is looking at several other research questions, including:
- To see if odronextamab works to destroy cancer cells
- Side effects that may be experienced by people taking odronextamab
- How odronextamab works in the body
- How much odronextamab is present in the blood
Official Title
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL)
Intervention / Treatment
- Drug: Odronextamab
Other Study ID Numbers
- R1979-ONC-1625
- 2017-002139-41
- 2024-511747-25-00
- 2017
Start Date (Actual)
2019-11-13
Primary Completion Date (Actual)
2026-06-17
Study Completion Date (Estimated)
2028-12-15
Enrollment (Actual)
515
Study Type
Interventional
Phase
Phase 2